Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, 65% of men with persistent sexual side effects after stopping finasteride reported a reduction in alcohol consumption, echoing findings in rodent models.

This study found that finasteride significantly improved hirsutism scores in women over 12 months and was well-tolerated with no serious side effects.

This study found that altering neonatal neurosteroid levels affected anxiety and aversive learning in adult rats, possibly through changes in hippocampal GABAergic functions.

Finasteride remains stable for two years with proper storage.

In this preliminary study, women with facial hirsutism treated with topically applied finasteride cream showed a significant decrease in hair growth and thickness compared to placebo, without adverse effects.

This study found that finasteride improved urodynamic measures of obstruction in men with benign prostatic enlargement and lower urinary tract symptoms, with continued improvement over two years of treatment.

This study reported that 6 months of finasteride treatment significantly improved idiopathic hirsutism in women, with benefits persisting 6 months post-treatment and no adverse reactions observed.

This review discusses adverse effects of 5 alpha-reductase inhibitors, particularly persistent side effects such as post-finasteride syndrome, and highlights the need for further investigation.

This study found that testosterone treatment in older hypogonadal men caused minor improvements in depressive symptoms and visuospatial memory, but overall, major cognitive benefits were not observed.

This study presents a validated HPTLC method for simultaneously determining five BPH drugs, showing high sensitivity and selectivity for potential use in quality-control analysis.

This study found that progesterone significantly delayed epileptogenesis development in a mouse model, and its effects were inhibited by finasteride, highlighting the potential role of neurosteroids in modifying epilepsy progression.

The researchers reported that they successfully developed and validated RP-HPLC and TLC methods for accurately measuring tamsulosin hydrochloride and finasteride in combination forms.

This study found that both finasteride and dutasteride act as slow, time-dependent inhibitors of steroid 5α-reductase type II, with dutasteride being more efficient, influenced by the enzyme's genetic variants.

This study reports that finasteride increases hair count by reactivating resting follicles in men with frontal male pattern hair loss, with continuous clinical improvement due to thickening and elongation of hair even after hair count stabilization.

Finasteride affects prostate weights and pituitary activity differently with age.

This study reported that prenatal exposure to dihydrotestosterone altered long-term androgen metabolism in juvenile male rats, suggesting different regulatory mechanisms for 5a-reductase in hypothalamic versus pituitary tissues.

In this study, oral finasteride treatment for four weeks reduced the weight of the corpus cavernosum in rats but did not significantly affect erectile function.

In this study, short-term finasteride treatment reduced apoptotic factors caspase-7 and IGFBP-3 in prostate cancer cells but did not significantly affect androgen receptor expression compared to placebo.

This study found that finasteride decreases DHT/T levels more significantly in the vertex scalp hair than in the occipital hair of patients with male pattern baldness.

This study concludes that rhesus macaques are a suitable model for testing the pharmacological properties of finasteride and other 5aR inhibitors, due to their biochemical similarity to humans.

This study found that nano-transferosomal gel formulations of finasteride improved its delivery across skin layers, potentially reducing major side effects associated with oral administration for treating male pattern baldness.

This study reported a significant increase in the reporting of sexual dysfunction associated with finasteride use, especially in individuals aged 31-45.

This case report describes a patient with frontal fibrosing alopecia experiencing significant hair regrowth and reversal of cutaneous atrophy after treatment with the 5α-reductase inhibitor finasteride.

This review discusses persistent sexual and nonsexual adverse effects of the 5α-reductase inhibitor finasteride in younger men, including erectile dysfunction, low libido, and depression. It reports no new clinical results but emphasizes further research is needed.

In this study, men taking 1 mg/day of finasteride for 12 months showed minor metabolic changes and slight improvements in glucose metabolism.

This study found that Transcutol P significantly enhanced the skin penetration of Finasteride in vitro, while cationic and anionic surfactants did not show such effects.

In this study, short-term treatment with lovastatin showed no effect on symptom severity, prostate volume, or PSA levels in men with prostatic enlargement from presumed benign prostatic hyperplasia.

This study found that finasteride (1 mg/day) appeared to reverse the shortening of the hair cycle in androgen sensitive sites but did not convert miniaturized hair into terminal hair.

This study demonstrated that 12 months of 5 mg daily finasteride treatment reduced prostate volume, dihydrotestosterone, and prostate-specific antigen levels, while improving urinary flow rates and symptom scores in benign prostatic hyperplasia patients.

This study describes the development of microneedle array patches for finasteride that released the drug over 7 to 14 days in vitro, suggesting a potential alternative to oral treatments for long-term management of benign prostatic hyperplasia and androgenic alopecia.